Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Epigenetic Therapy Promotes the Ratio of Th1/Th17 Lineage to Reverse Immune Evasion and Treat Leukemia Relapse Post-allogeneic Stem Cell Transplantation in Non-APL AML Patients

Autor: Yang Xi, Dai Jingying, Li Chenglong, Zheng Hong, Zhang Rong, Wang Xiaodong, Wang Chunsen, Huang Xiaobing

Publikováno v: Frontiers in Molecular Biosciences, Vol 7 (2021)

To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (exclud

Externí odkaz: https://doaj.org/article/826d45dbe22c4d6faf52e8a023eea785

Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era

Autor: Ronald Sobecks, Deepa Jagadeesh, Faiz Anwer, Lisa Rybicki, Navneet S. Majhail, Brad Pohlman, Aaron T. Gerds, Sanghee Hong, Betty K. Hamilton, Matt Kalaycio, Donna Corrigan, Brian T. Hill, Robert M. Dean

Publikováno v: Hematology/Oncology and Stem Cell Therapy, Vol 14, Iss 4, Pp 318-326 (2021)

Objective/Background: Relapse is the most common cause of treatment failure after allogeneic hematopoietic cell transplantation (alloHCT). No standard of care exists, and a wide range of treatments are used for post-alloHCT relapse. In the recent era

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::481dcdf84e0fb8754d584e6aac05bec4
http://www.sciencedirect.com/science/article/pii/S1658387620301783

Prognostic factors for survival in children who relapsed after allogeneic hematopoietic stem cell transplantation for acute leukemia

Autor: Şebnem Yılmaz, Suar Çakı Kılıç, Alphan Kupesiz, Volkan Hazar, Savaş Kansoy, Fatma Visal Okur, Musa Karakukcu, Orhan Gürsel, Ibrahim Bayram, Vedat Uygun, Yöntem Yaman, Ceyhun Bozkurt, Elif Güler, Arzu Akcay, Gülyüz Öztürk, Mehmet Ertem, Gülsün Karasu, Müge Gökçe, Duygu Uckan, Tunç Fışgın, Namik Ozbek, Talia Ileri, Barbaros Şahin Karagün, Akif Yeşilipek, Serap Aksoylar, Ülker Koçak, Tekin Aksu

Background: Post-transplant relapse has a dismal prognosis in children with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Data on risk factors, treatment options, and outcomes are limited. Procedure: In thi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4835e96266c7150eceb04e19c0a22c31
https://hdl.handle.net/11454/70090

GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation

Autor: Tiago Nava, Nicolas Waespe, Jaap Jan Boelens, Hadrien Golay, Henrique Bittencourt, Maja Krajinovic, Vid Mlakar, Christina Peters, Yves Chalandon, Marc Ansari, Mohamed-Ali Rezgui, Chakradhara Rao Uppugunduri Satyanarayana, Selim Corbacioglu, Jean-Hugues Dalle, Shannon Robin, R.G.M. Bredius, Simona Jurkovic Mlakar

Publikováno v: Journal of Cancer Research and Clinical Oncology
Journal of Cancer Research and Clinical Oncology, 148, 71-86. SPRINGER
Jurkovic Mlakar, Simona; Uppugunduri, Satyanarayana Chakradhara Rao; Nava, Tiago; Mlakar, Vid; Golay, Hadrien; Robin, Shannon; Waespe, Nicolas; Rezgui, Mohamed Aziz; Chalandon, Yves; Boelens, Jaap Jan; Bredius, Robert G M; Dalle, Jean-Hugues; Peters, Christina; Corbacioglu, Selim; Bittencourt, Henrique; Krajinovic, Maja; Ansari, Marc (2022). GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. Journal of cancer research and clinical oncology, 148(1), pp. 71-86. Springer 10.1007/s00432-021-03769-2
Journal of cancer research and clinical oncology, Vol. 148, No 1 (2022) pp. 71-86

Purpose This study aimed to retrospectively evaluate the genetic association of null variants of glutathione S-transferases GSTM1 and GSTT1 with relapse incidence in children with hematological malignancies (HMs) undergoing busulfan (BU)- containing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7486d1704cfb6d65e7f4a50c7b7aa49f
https://hdl.handle.net/1887/3277451